These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 31394114

  • 1. Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection.
    Vella V, Malaguarnera R, Nicolosi ML, Morrione A, Belfiore A.
    Biochim Biophys Acta Mol Cell Res; 2019 Nov; 1866(11):118522. PubMed ID: 31394114
    [Abstract] [Full Text] [Related]

  • 2. A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer.
    Belfiore A, Malaguarnera R, Nicolosi ML, Lappano R, Ragusa M, Morrione A, Vella V.
    Cell Adh Migr; 2018 Nov; 12(4):305-314. PubMed ID: 29486622
    [Abstract] [Full Text] [Related]

  • 3. Discoidin domain receptors: Micro insights into macro assemblies.
    Agarwal G, Smith AW, Jones B.
    Biochim Biophys Acta Mol Cell Res; 2019 Nov; 1866(11):118496. PubMed ID: 31229648
    [Abstract] [Full Text] [Related]

  • 4. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2.
    Leitinger B.
    J Biol Chem; 2003 May 09; 278(19):16761-9. PubMed ID: 12611880
    [Abstract] [Full Text] [Related]

  • 5. DDR1 Affects Metabolic Reprogramming in Breast Cancer Cells by Cross-Talking to the Insulin/IGF System.
    Vella V, Giuliano M, Nicolosi ML, Majorana MG, Marć MA, Muoio MG, Morrione A, Maggiolini M, Lappano R, De Francesco EM, Belfiore A.
    Biomolecules; 2021 Jun 22; 11(7):. PubMed ID: 34206590
    [Abstract] [Full Text] [Related]

  • 6. Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells.
    Vella V, Malaguarnera R, Nicolosi ML, Palladino C, Spoleti C, Massimino M, Vigneri P, Purrello M, Ragusa M, Morrione A, Belfiore A.
    Oncotarget; 2017 Jun 27; 8(26):43248-43270. PubMed ID: 28591735
    [Abstract] [Full Text] [Related]

  • 7. The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives.
    Vella V, Malaguarnera R.
    Int J Mol Sci; 2018 Nov 30; 19(12):. PubMed ID: 30513575
    [Abstract] [Full Text] [Related]

  • 8. DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop.
    Vella V, Nicolosi ML, Cantafio P, Massimino M, Lappano R, Vigneri P, Ciuni R, Gangemi P, Morrione A, Malaguarnera R, Belfiore A.
    Endocr Relat Cancer; 2019 Jan 01; 26(1):197-214. PubMed ID: 30121624
    [Abstract] [Full Text] [Related]

  • 9. DDR1 and DDR2 physical interaction leads to signaling interconnection but with possible distinct functions.
    Croissant C, Tuariihionoa A, Bacou M, Souleyreau W, Sala M, Henriet E, Bikfalvi A, Saltel F, Auguste P.
    Cell Adh Migr; 2018 Jan 01; 12(4):324-334. PubMed ID: 29616590
    [Abstract] [Full Text] [Related]

  • 10. Clustering, Spatial Distribution, and Phosphorylation of Discoidin Domain Receptors 1 and 2 in Response to Soluble Collagen I.
    Yeung DA, Shanker N, Sohail A, Weiss BA, Wang C, Wellmerling J, Das S, Ganju RK, Miller JLC, Herr AB, Fridman R, Agarwal G.
    J Mol Biol; 2019 Jan 18; 431(2):368-390. PubMed ID: 30458172
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model.
    Bansod S, Saifi MA, Godugu C.
    Sci Rep; 2021 Jun 18; 11(1):12894. PubMed ID: 34145346
    [Abstract] [Full Text] [Related]

  • 12. Novel insights into the role of Discoidin domain receptor 2 (DDR2) in cancer progression: a new avenue of therapeutic intervention.
    Trono P, Ottavi F, Rosano' L.
    Matrix Biol; 2024 Jan 18; 125():31-39. PubMed ID: 38081526
    [Abstract] [Full Text] [Related]

  • 13. Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation.
    Denny WA, Flanagan JU.
    Biomolecules; 2021 Nov 10; 11(11):. PubMed ID: 34827669
    [Abstract] [Full Text] [Related]

  • 14. New Concepts on the Interactions of Discoidin Domain Receptors with Collagen.
    Fridman R, Agarwal G.
    Biochim Biophys Acta Mol Cell Res; 2019 Nov 10; 1866(11):118527. PubMed ID: 31400359
    [No Abstract] [Full Text] [Related]

  • 15. A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril.
    Orgel JPRO, Madhurapantula RS.
    Biochim Biophys Acta Mol Cell Res; 2019 Nov 10; 1866(11):118478. PubMed ID: 31004686
    [Abstract] [Full Text] [Related]

  • 16. The D2 period of collagen II contains a specific binding site for the human discoidin domain receptor, DDR2.
    Leitinger B, Steplewski A, Fertala A.
    J Mol Biol; 2004 Dec 03; 344(4):993-1003. PubMed ID: 15544808
    [Abstract] [Full Text] [Related]

  • 17. The discoidin domain receptor DDR2 is a receptor for type X collagen.
    Leitinger B, Kwan AP.
    Matrix Biol; 2006 Aug 03; 25(6):355-64. PubMed ID: 16806867
    [Abstract] [Full Text] [Related]

  • 18. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.
    Matà R, Palladino C, Nicolosi ML, Lo Presti AR, Malaguarnera R, Ragusa M, Sciortino D, Morrione A, Maggiolini M, Vella V, Belfiore A.
    Oncotarget; 2016 Feb 16; 7(7):7683-700. PubMed ID: 26655502
    [Abstract] [Full Text] [Related]

  • 19. Collagen binding specificity of the discoidin domain receptors: binding sites on collagens II and III and molecular determinants for collagen IV recognition by DDR1.
    Xu H, Raynal N, Stathopoulos S, Myllyharju J, Farndale RW, Leitinger B.
    Matrix Biol; 2011 Jan 16; 30(1):16-26. PubMed ID: 21044884
    [Abstract] [Full Text] [Related]

  • 20. Collagen recognition and transmembrane signalling by discoidin domain receptors.
    Carafoli F, Hohenester E.
    Biochim Biophys Acta; 2013 Oct 16; 1834(10):2187-94. PubMed ID: 23128141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.